7月31日，医疗美容概念上涨0.43%，今日主力资金流入2.44亿元，概念股24只上涨，46只下跌。 主力资金净流入居前的分别为安科生物（4.03亿元）、常山药业（2.5亿元）、汉商集团（1.1亿元）、 乐普医疗（6230.96万元）、振东制药（4677.6万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300009安科生物12.1120.024.03亿元10.5%2300255常 山药业42.33.172.50亿元9.44%3600774汉商集团11.3310.01.10亿元40.97%4300003乐普医疗 15.560.846230.96万元5.49%5300158振东制药8.6216.644677.60万元2.15%6300238冠昊生物 17.41.163491.91万元8.34%7300753爱朋医疗31.397.283162.54万元5.27%8000725京东方Ａ4.04- 0.982808.99万元1.6%9000935四川双马19.550.572758.18万元9.8%10300244迪安诊断16.11.582710.14万元 4.4% 来源：金融界 ...

作者：金股通 截至7月31日收盘回顾，主力资金流入前20的股票分别为：三六零（11.33亿元）、易点天下（8.89亿 元）、用友网络（8.81亿元）、诺德股份（8.05亿元）、神州数码（7.60亿元）、天风证券（7.20亿 元）、长城军工（6.84亿元）、剑桥科技（6.81亿元）、拓维信息（6.16亿元）、寒武纪U（5.79亿 元）、利欧股份（5.47亿元）、XD工业富（5.43亿元）、浪潮信息（5.03亿元）、长盈精密（4.92亿 元）、川润股份（4.51亿元）、南兴股份（4.20亿元）、安科生物（4.03亿元）、农业银行（3.73亿 元）、昆仑万维（3.65亿元）、华胜天成（2.85亿元）。 本文源自：金融界 ...

Market Overview - On July 31, the A-share market closed with the Shanghai Composite Index at 3573.21, down 1.18%, and the Shenzhen Component Index at 11009.77, down 1.73% [1] Top Stocks Performance - Among the top 10 stocks in the ChiNext board by trading volume, 6 stocks saw gains with an average increase of 6.52%. Xinyi Technology (300502) led with a trading volume of 14.605 billion yuan [1] - In terms of net capital inflow, 4 out of the top 10 stocks experienced positive net inflow [1] Individual Stock Data - Xinyi Technology (300502): Latest price 189.21, down 0.60%, trading volume 14.605 billion yuan, net outflow -5.25 million yuan [2] - Zhongji Xuchuang (300308): Latest price 217.61, up 3.33%, trading volume 14.275 billion yuan, net outflow -2.39 million yuan [2] - Ningde Times (300750): Latest price 264.62, down 4.50%, trading volume 12.089 billion yuan, net outflow -16.63 million yuan [2] - Shenghong Technology (300476): Latest price 192.08, up 0.01%, trading volume 10.911 billion yuan, net inflow 10.196 million yuan [2] - Dongfang Caifu (300059): Latest price 23.23, down 2.44%, trading volume 10.438 billion yuan, net outflow -16.97 million yuan [2] - Tianhu Communication (300394): Latest price 105.63, up 3.87%, trading volume 7.019 billion yuan, net inflow 8.361 million yuan [2] - Changying Precision (300115): Latest price 22.72, up 8.86%, trading volume 4.784 billion yuan, net inflow 4.92 million yuan [2] - Zhizhen (300803): Latest price 88.77, down 3.50%, trading volume 3.893 billion yuan, net outflow -6.31 million yuan [2] - Anke Bio (300009): Latest price 12.11, up 20.02%, trading volume 3.834 billion yuan, net inflow 4.03 million yuan [2] - Kunlun Wanwei (300418): Latest price 35.90, up 3.01%, trading volume 3.699 billion yuan, net inflow 3.65 million yuan [2] ETF Performance - Food and Beverage ETF (Product Code: 515170): Recent five-day change -0.51%, PE ratio 20.31, latest shares 5.78 billion, increased by 45 million shares, net outflow -95.6 thousand yuan [5] - Gaming ETF (Product Code: 159869): Recent five-day change 2.52%, PE ratio 43.69, latest shares 7.04 billion, increased by 320 million shares, net inflow 1.5936 million yuan [5] - Semiconductor ETF (Product Code: 588170): Recent five-day change 2.16%, latest shares 370 million, increased by 2 million shares, net outflow -885.6 thousand yuan [5] - Cloud Computing 50 ETF (Product Code: 516630): Recent five-day change 3.33%, PE ratio 115.52, latest shares 440 million, increased by 3 million shares, net outflow -78.1 thousand yuan [6]

Market Overview - The A-share market experienced a decline with the Shanghai Composite Index falling by 1.18%, the Shenzhen Component Index down by 1.73%, and the ChiNext Index decreasing by 1.66% [1][2] - The total trading volume in the Shanghai and Shenzhen markets reached 1.94 trillion yuan, an increase of 91.7 billion yuan compared to the previous trading day, with over 4,200 stocks declining [1][2] Sector Performance - Sectors such as steel, energy metals, coal mining and processing, photovoltaic equipment, and film and television cinema saw declines, while the liquid cooling server sector showed strong performance [4] - The innovative drug concept continued to perform well, with several stocks including Nanxin Pharmaceutical, Anke Bio, and Aoxiang Pharmaceutical hitting the daily limit [4] - The liquid cooling server concept had multiple stocks, including Yingweike and Icewheel Environment, reaching the daily limit [4][5] Capital Flow - Major funds saw net inflows in sectors like banking, computers, and traditional Chinese medicine, while there were net outflows in mining, paper printing, and electronic components [6] - Specific stocks such as 360, Yidian Tianxia, and Yongyou Network received net inflows of 1.133 billion yuan, 889 million yuan, and 881 million yuan respectively [6] - Conversely, Baogang Group, Dongfang Fortune, and CATL faced net outflows of 1.868 billion yuan, 1.697 billion yuan, and 1.663 billion yuan respectively [6] Institutional Insights - Galaxy Securities suggests not to make bullish moves while the Shanghai Composite Index is below the 5-day moving average, indicating a high probability of filling the gap [6] - Everbright Securities notes that market sentiment remains active, with fluctuations being a normal adjustment within the trend [7] - CITIC Securities maintains that the index is expected to continue its upward trend despite short-term fluctuations [7]

金融界消息 截至2025年7月31日收盘，安科生物（300009）报收于12.11元，上涨20.02%，换手率 27.06%，成交量330.56万手，成交金额38.34亿元。 资金流向方面，今日主力资金净流入4.03亿元，占比成交额10.5%。其中，超大单净流入6.49亿元、占 成交额16.92%，大单净流出24587.28万元、占成交额6.41%，中单净流出流出41781.77万元、占成交额 10.9%，小单净流入1511.15万元、占成交额0.39%。 安科生物最新一期业绩显示，截至2025一季报，公司营业总收入6.29亿元、同比减少4.17%，归属净利 润2.09亿元，同比减少4.02%，扣非净利润1.97亿元，同比减少3.92%，流动比率3.071、速动比率 2.647、资产负债率16.52%。 天眼查商业履历信息显示，安徽安科生物工程(集团)股份有限公司，成立于2000年，位于合肥市，是一 家以从事研究和试验发展为主的企业。企业注册资本167255.3658万人民币，实缴资本2400万人民币。 公司法定代表人为宋礼华。 通过天眼查大数据分析，安徽安科生物工程(集团)股份有限公司共对外投资了24家企业 ...

Group 1 - The core viewpoint of the news is the strong performance of reproductive health-related stocks in both the Hong Kong and A-share markets, driven by new government policies aimed at enhancing reproductive health services [1] - The Beijing Municipal Government has issued a notice to improve the reproductive support policy system, which includes optimizing maternal and child healthcare resources and enhancing reproductive health technology [1] - Specific measures include the inclusion of suitable assisted reproductive technology projects in medical insurance coverage and the establishment of "birth-friendly" hospitals to improve the childbirth experience [1] Group 2 - Notable stock performances include: - Tonghua Pharmaceutical (共同药业) with a 19.99% increase and a market cap of 2.837 billion [2] - Lide Man (利德曼) rising by 19.93% with a market cap of 3.830 billion [2] - Anke Biotechnology (安科生物) increasing by 18.14% with a market cap of 19.9 billion [2] - Other companies such as Han Commercial Group (汉商集团) and Luoxin Pharmaceutical (罗欣药业) also saw significant gains, with both reaching the 10% limit up [1][2] - The overall trend indicates a positive market sentiment towards companies involved in reproductive health, with many stocks showing substantial year-to-date increases [2]

Group 1 - The core viewpoint of the news is the introduction of a nationwide childcare subsidy program aimed at supporting families with eligible infants born after January 1, 2022, which is expected to stimulate consumption in the maternal and infant sectors [1][2] - The central government has allocated an initial budget of approximately 90 billion yuan for the childcare subsidy program, with the central finance covering about 90% of the funding needed for the basic standard subsidy [2] - The announcement has led to a significant increase in stock prices of companies in the assisted reproduction and maternal-infant sectors, with companies like Gongtong Pharmaceutical and Lide Man reaching a 20% limit-up [1] Group 2 - The subsidy program is described as a major initiative for public welfare, providing direct cash benefits to families regardless of urban or rural status, ethnicity, or the number of children [1] - Short-term effects of the subsidy are expected to directly stimulate consumption in related sectors such as baby care, dairy products, toys, and children's clothing [2] - Long-term implications include an increase in birth rates and improved willingness to have children, which may benefit the entire maternal and infant industry chain, including assisted reproduction, genetic testing, childcare services, and education [2]

Core Viewpoint - The A-share assisted reproductive sector is experiencing significant growth, with multiple companies reaching new highs and notable stock price increases [1] Company Performance - Fuyuan Pharmaceutical reached an all-time high during trading [1] - Gongtong Pharmaceutical, Hanshang Group, and Lide Man all hit the daily limit up [1] - Anke Bio increased by over 15% [1] - Guangshengtang rose by over 10% [1] - Other companies such as Xinguang Pharmaceutical, Dajia Weikang, BeiYinMei, Xinghao Pharmaceutical, and Beirui Gene also saw price increases [1]

Group 1 - The A-share innovative drug concept stocks continue to rise, with Nanxin Pharmaceutical hitting the 20% daily limit up [1] - Qizheng Tibetan Medicine and Hanshang Group also reached the daily limit up, indicating strong market interest [1] - Other companies such as Hitec Biological, Anke Biological, Huisheng Biological, Zhendong Pharmaceutical, Tebao Biological, and Treasure Island saw increases of over 5% [1]

（文章来源：每日经济新闻） 每经AI快讯，7月31日，创新药概念股持续活跃，南新制药20%涨停，奇正藏药、汉商集团涨停，海特 生物、安科生物、回盛生物、振东制药、特宝生物、珍宝岛等涨超5%。 ...